Effective treatments for early-stage hepatocellular carcinoma (HCC) have provided the rationale for HCC surveillance since detection of the disease at an early stage is associated with more favorable outcome. In a prospective multi-institutional diagnostic study, Park et al. (1) evaluated the added value of (perfluorobutane) contrast-enhanced ultrasound (CEUS) when combined with conventional B-mode ultrasound (US) as an HCC surveillance tool in participants with liver cirrhosis using a single arm, intraindividual comparison study design. The primary end points were the detection rate of early-stage HCC (Barcelona clinic liver cancer staging system stage 0 or A) and false-positive rate. Of the initially included 524 participants, 493 (94.1%) had liver cirrhosis related to the hepatitis B virus (HBV). Ten HCCs were confirmed in eight participants. The detection rate for early-stage HCC was not significantly improved by adding perfluorobutaneenhanced US to conventional B-mode US. However, the false-positive rate was significantly reduced.Some current clinical practice guidelines also recommend HCC surveillance in patients with chronic hepatitis C virus (HCV) infection and advanced liver fibrosis (stage F3) (2). Chronic HBV without cirrhosis is considered an indication for HCC surveillance if any of the following criteria is met (2-6): Active hepatitis [e.g., elevated serum alanine transaminase (ALT)] and/or high viral load (i.e., >100,000 copies/mL). Family history of HCC [first degree relative, adjusted rate ratio (ARR) 2.4] (7). Asian males over the age of 40 years, females over 50 years. The incidence of HCC in Asian patients with HBV is higher than in Caucasian patients (0.4 to 0.6 percent per year compared to less than 0.2 percent per year) (8,9). The incidence in male HBV carriers from Southeast Asia exceed 0.2% around the age of 40 years and is the basis for the recommendation that surveillance start in Asian men at age 40 years. The incidence in Asian women is lower, but it is not well defined. Africans and African Americans (10,11). Viral load >100,000 copies/mL (20,000 international units/mL) is a risk factor for disease progression and HCC in Asian patients (4-6). Also, surveillance is recommended for patients who are on effective antiviral treatment for chronic HBV infection and are HBsAg seropositive, although the risk of HCC appears to be decreased among these patients (2,3). In contrast, the incidence of HCC is low for treatmentnaïve patients with inactive hepatitis (long-term normal ALT and HBV DNA levels less than 2,000 international units/mL) (12,13). As a result, surveillance for such patients without cirrhosis and without an additional risk factor